Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T14:42:18.893Z.
Calculation as of: 2026-10-06T14:42:18.893Z.
Quote observation: 2026-10-06T14:40:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc00e8cb63dba40c56ed5fb80588e73c180b52fe93b8081d2416c5f575d95e45
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Insight Molecular Diagnostics Inc.
Market Cap
$117.21M
Free Cash Flow Yield
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD |
|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $117.21M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.11M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.72M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.22M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | N/A |
| Genelux Corporation (GNLX)vs › | $114.34M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.23M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $122.96M | N/A |
| Cibus, Inc. (CBUS)vs › | $123.66M | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
